RECIST 1.1 hedef lezyon seçimi ve yanıt

Özet

RECIST 1.1, solid tümörlü hastalarda anatomik görüntüleme üzerinden tedavi yanıtını standart biçimde sınıflandırmak için kullanılır; klinik uygulamadaki kullanımı her zaman tedavi protokolü ve tümör tipine özgü kurallarla birlikte düşünülmelidir. Başlangıçta seçilen ölçülebilir odaklar sonraki BT’lerde aynı tanımla ve aynı ölçüm ekseninde izlenir. Lenf düğümünde kısa aks, diğer hedef lezyonlarda uzun çap toplam yanıt hesabına girer. Yeni lezyonun veya hedef dışı hastalıkta belirgin ilerlemenin atlanması toplam çaplar küçülmüş olsa bile progresyonun gözden kaçmasına yol açar.

Faz ve pencere

Portal tanısal

Toraks-abdomen-pelviste ölçülebilir yumuşak doku ve nodal odakların sınırları kontrastlı BT serilerinde kaydedilir. RECIST 1.1, ölçümün tekrarlanabilirliği için kontrastlı BT kullanımını önerir ve seri incelemelerde görüntüleme parametrelerinin tutarlı olmasını gerektirir. RECIST 1.1, ölçümün tekrarlanabilirliği için kontrastlı BT kullanımını önerir ve ölçümlerin edinim düzleminde tutarlı olarak yapılmasını şart koşar. Olguların çoğunda RECIST 1.1 uygulanır; ancak hepatoselüler karsinom (mRECIST) veya gastrointestinal stromal tümörler (Choi kriterleri) gibi özel tümör tipleri için farklı yanıt değerlendirme kriterleri kullanılabilir.

Önerilen pencereler: Akciğer (G 1500 / M -600), Mediasten (G 350 / M 50), Batın (G 400 / M 50), Karaciğer (G 150 / M 30), Kemik (G 1800 / M 400), Yumuşak doku (G 400 / M 40).

BT bulguları

• Hedef lezyon — tümör yükünü temsil eden, sınırları seçilebilen ve sonraki kesitlerde güvenilir biçimde yeniden bulunabilen ölçülebilir odak.
• Solid organ veya akciğer kitlesi — aksiyel görüntüde uzun çap ölçülür; aynı düzlem ve lezyon tanımlayıcısı kontrollerde korunur.
• Hedef lenf düğümü — kısa aks ölçülür ve çap toplamına katılır; başlangıç hedef seçimi için kısa aks ≥ 15 mm eşik alınır.
• Hedef dışı hastalık — ölçülebilir eşik altında kalan odaklar, kemik lezyonları veya efüzyon gibi ölçülemeyen bulgular ayrı başlıkta izlenir.
• Yeni lezyon — önceki incelemede bulunmayan ve gerçek yeni hastalık olarak kabul edilebilir odak; hedef toplamı dışında ayrıca tanımlanır.
• Hedef dışı açık progresyon — küçük çap değişimleri değil, tümör yükünde belirgin ve tartışmasız artış karar için önem taşır.
• Kemik metastazı — yumuşak doku bileşeni ölçülebilir hedef olabilir; yalnız litik veya sklerotik kemik odağı çoğu durumda çap toplamına girmez.

Ölçütler ve sınıflamalar

Toplam seçilebilir hedef lezyon sayısı; en çok iki hedef/organ

5 lezyon

Solid lezyonda ölçülebilir hedef alt sınırı; kesit kalınlığı ≤5 mm

10 mm uzun çap

Kesit kalınlığı >5 mm olduğunda solid lezyon alt sınırı

2 × kesit kalınlığı

Hedef lenf düğümü

≥15 mm kısa aks

Kısmi yanıt

Başlangıç toplam çapında ≥%30 azalma

Progresif hastalık

En küçük toplam çapa göre ≥%20 artış ve mutlak ≥5 mm artış

RECIST 1.1 genel yanıt kategorileri

Tam yanıt (CR): hedef lezyonlar kaybolur ve patolojik hedef lenf düğümleri kısa aksta <10 mm olur. Kısmi yanıt (PR): başlangıçtaki hedef çapları toplamında en az %30 azalma. Progresif hastalık (PD): en küçük toplamdan en az %20 ve mutlak 5 mm artış, kesin yeni lezyon veya hedef dışı hastalıkta tartışmasız ilerleme. Stabil hastalık (SD): PR ya da PD eşiğine ulaşmayan değişim.

Normalde

Normal toraks ve batın BT’de lenf düğümleri oval, yağlı hilusu korunmuş ve kısa aksları patolojik boyutta değildir; karaciğer ve akciğer parankiminde fokal kitle görülmez. Solid odaklarda ve lenf düğümlerindeki ölçümler, genellikle aksiyel düzlemde (izotropik rekonstrüksiyon yoksa) alınmalı ve tekrarlanabilirliği açısından tutarlı planlama kullanılmalıdır. Normal görünen boyuttaki lenf düğümü RECIST değerlendirmesinde patolojik hedef sayılmaz.

Ayırıcı tanı

Kaviter enfeksiyöz akciğer odağı

çevresel konsolidasyon veya hava-sıvı içeriği metastatik solid nodüle karşı ipucu verir.

Tedavi sonrası fibrozis

bilinen radyasyon alanında çizgisel veya çekintili doku kitlesel canlı tümörle karıştırılabilir.

Tuzaklar

• Lenf düğümünün uzun aksını ölçmek, RECIST toplamına yanlış çap ekler; nodal ölçüm daima kısa akstan yapılır.
• Kontrol BT’de hedef dışı tek bir küçük odağın artması kendiliğinden PD değildir; değişim tüm hastalık yükünde açık ilerleme oluşturmalıdır.
• Yeni sklerotik kemik odağı tedavi yanıtı sırasında iyileşme sklerozu olabilir; eski seri ve eşlik eden litik/yumuşak doku bileşeniyle karşılaştırın.
• RECIST çapı anatomik tümör boyutunu ölçer; bazı etkili sitostatik tedavilerde tümör boyutunda belirgin değişiklik olmayabilir.

Kendini dene

1. Kontrol incelemede hedef çap toplamı başlangıca göre azalıyor; ancak önceki seride olmayan kesin yeni karaciğer metastazı var. RECIST 1.1 yanıtı nedir?

   • Progresif hastalık
   • Kısmi yanıt
   • Stabil hastalık
   • Tam yanıt
   Cevabı göster

   Progresif hastalık. Kesin yeni lezyon progresyon ölçütüdür; hedef çaplarının azalması yeni hastalığın sınıflamaya etkisini ortadan kaldırmaz. PR yalnız hedef çap toplamındaki azalmaya, SD eşik dışı değişime dayanır.

2. RECIST 1.1'de bir lenf düğümünün takip ölçümünde hangi aks kullanılır?

   • Kısa aks
   • Uzun aks
   • İki çapın toplamı
   • Hacim
   Cevabı göster

   Kısa aks. Lenf düğümleri RECIST 1.1’de kısa aks üzerinden ölçülür; hedef lenf düğümü için başlangıç ölçüm eşiği 15 mm kısa akstır. Uzun aks, çapların toplamı ve hacim nodal ölçüm ölçütü değildir.

Bu konunun yer aldığı turlar

• Onkolojik BT: evreleme ve yanıt değerlendirmesi

İlgili konular

• Onkolojik BT’de bazal inceleme ve izlem

Kaynaklar

Bu sayfadaki 47 cümle ve 2 quiz sorusu aşağıdaki kaynaklardan alıntılarla tek tek karşılaştırıldı; 6 cümle bu karşılaştırmada düzeltildi (2026-10-08).

1. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCISTpmc.ncbi.nlm.nih.gov
2. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.pubmed.ncbi.nlm.nih.gov
3. 68 Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.pubmed.ncbi.nlm.nih.gov
4. The prognostic role of whole-body volumetric 68 GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177 LU-DOTATATE.pubmed.ncbi.nlm.nih.gov
5. Prediction of [ 177 Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [ 177 Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour.pubmed.ncbi.nlm.nih.gov
6. Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study.pubmed.ncbi.nlm.nih.gov
7. Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials.pubmed.ncbi.nlm.nih.gov
8. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach.pubmed.ncbi.nlm.nih.gov
9. Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1.pubmed.ncbi.nlm.nih.gov
10. A CT Dataset with RECIST Measurements and Comprehensive Segmentation Masks for Tumors and Lymph Nodes.pubmed.ncbi.nlm.nih.gov
11. ESR Essentials: response assessment criteria in oncologic imaging-practice recommendations by the European Society of Oncologic Imaging.pubmed.ncbi.nlm.nih.gov
12. Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.pubmed.ncbi.nlm.nih.gov
13. HAIC-Based Combination Therapy for Advanced Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombus and Child-Pugh B Liver Function: A Case Report.pubmed.ncbi.nlm.nih.gov
14. Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study.pubmed.ncbi.nlm.nih.gov
15. Safety and Efficacy of Adebrelimab plus Apatinib Combined with Hepatic Artery Infusion Chemotherapy for the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.pubmed.ncbi.nlm.nih.gov
16. Radiologic Response Assessment With RECIST 1.1 and mRECIST in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.pubmed.ncbi.nlm.nih.gov
17. Multicenter AI- versus expert-assisted RECIST target lesion measurements in follow-up body CT of patients with cancer.pubmed.ncbi.nlm.nih.gov
18. Assessing the reliability of Response Evaluation Criteria In Solid Tumors (RECIST): a systematic review of the factors contributing to inter-observer variability.pubmed.ncbi.nlm.nih.gov
19. Medical imaging in immunotherapy response evaluation: from RECIST to AI-driven longitudinal models, and the distinction between risk prediction and kinetic diagnosis.pubmed.ncbi.nlm.nih.gov
20. WiNGPT-32B: An Open-Source, Locally Deployable LLM for RECIST Assessment via Chained Task Execution Using Radiology Report Text.pubmed.ncbi.nlm.nih.gov
21. Pretreatment prognostic nutritional index and immune status for response to preoperative neoadjuvant chemotherapy in cervical squamous cell carcinoma: an exploratory retrospective study.pubmed.ncbi.nlm.nih.gov
22. Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib.pubmed.ncbi.nlm.nih.gov
23. A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report.pubmed.ncbi.nlm.nih.gov
24. Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification.pubmed.ncbi.nlm.nih.gov
25. Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review.pubmed.ncbi.nlm.nih.gov
26. Minimal residual disease and relapse surveillance in osteosarcoma: an action-linked framework integrating liquid biopsy and imaging biomarkers.pubmed.ncbi.nlm.nih.gov
27. Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors.pubmed.ncbi.nlm.nih.gov
28. Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study.pubmed.ncbi.nlm.nih.gov
29. Stereotactic body radiation therapy for hepatocellular carcinoma: 2026 expert consensus-based practical recommendation of the Korean Liver Cancer Association.pubmed.ncbi.nlm.nih.gov
30. The role of stereotactic body radiotherapy in the management of hepatocellular carcinoma with macroscopic vascular invasion: a narrative review.pubmed.ncbi.nlm.nih.gov
31. Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma.pubmed.ncbi.nlm.nih.gov
32. Commentary: an eye on PET quantification.pubmed.ncbi.nlm.nih.gov
33. Long-term safety and effectiveness of the "OptEase" vena cava filter.pubmed.ncbi.nlm.nih.gov
34. Immune checkpoint inhibition in bone metastases: lesion response heterogeneity, the osteoimmune niche, and microenvironment-directed therapy.pubmed.ncbi.nlm.nih.gov
35. Automated model-based lesion tracking in CT: colorectal liver metastases as a use case for development and performance analysis.pubmed.ncbi.nlm.nih.gov
36. A Chemotherapy Progression Decision Score for Treatment Selection After Initial Assessment in Pancreatic Ductal Adenocarcinoma.pubmed.ncbi.nlm.nih.gov
37. Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non-head-and-neck cutaneous squamous cell carcinoma.pubmed.ncbi.nlm.nih.gov
38. Deep Learning Quality Control for RECIST-Oriented Assessment: A Vision Transformer Predicts Inter-Reader Variability of Unidimensional Lesion Measurements on Contrast CT.pubmed.ncbi.nlm.nih.gov
39. Defining the abscopal effect in non-small cell lung cancer in the era of immunotherapy and lung ablation treatment: a narrative review.pubmed.ncbi.nlm.nih.gov
40. Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study.pubmed.ncbi.nlm.nih.gov
41. Challenges in tracer development for tumor microenvironment (TME) imaging.pubmed.ncbi.nlm.nih.gov
42. Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer.pubmed.ncbi.nlm.nih.gov
43. Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.pubmed.ncbi.nlm.nih.gov
44. Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.pubmed.ncbi.nlm.nih.gov
45. Efficacy and Safety of Moderate-Dose Stereotactic Body Radiation Therapy (SBRT) for Patients with Oligometastatic Lung Cancer Unfit for Standard SBRT: A Preliminary Single-Center Study.pubmed.ncbi.nlm.nih.gov
46. Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society.pubmed.ncbi.nlm.nih.gov
47. Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.pubmed.ncbi.nlm.nih.gov
48. CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma.pubmed.ncbi.nlm.nih.gov
49. The legend of the response evaluation criteria in solid tumors: A historical overview.pubmed.ncbi.nlm.nih.gov
50. A Foundation Model Based CT Biomarker for Non-Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non-Small Cell Lung Cancer.pubmed.ncbi.nlm.nih.gov
51. Radiomics-Based Prediction of Treatment Response in Non-Small Cell Lung Cancer Using Pre-Treatment CT Imaging Features.pubmed.ncbi.nlm.nih.gov
52. Computed tomographic Characteristics of Presumed Normal Canine Iliosacral Lymph Nodes.pubmed.ncbi.nlm.nih.gov
53. Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.pubmed.ncbi.nlm.nih.gov
54. Pulsed Electric Field Ablation for Advanced Lung and Oligometastatic Disease: A Retrospective Study of 32 Consecutive Patients in a Community Hospital Setting.pubmed.ncbi.nlm.nih.gov
55. Safety and efficacy of drug-eluting beads versus conventional bronchial arterial chemoembolization for lung cancer: a systematic review and meta-analysis.pubmed.ncbi.nlm.nih.gov
56. Hypofractionated radiotherapy for localized prostate cancer.pubmed.ncbi.nlm.nih.gov
57. High-affinity alphavbeta3 integrin targeted optical probe as a new imaging biomarker for early atherosclerosis: initial studies in Watanabe rabbits.pubmed.ncbi.nlm.nih.gov
58. A Rare Case of Hodgkin Lymphoma With Isolated Epitrochlear Lymphadenopathy. Our Experience and Main Differential Diagnosis.pubmed.ncbi.nlm.nih.gov
59. Anatomy, Imaging, and Surgical Treatment of Thoracic Lymphadenopathies in Advanced Epithelial Ovarian Cancer.pubmed.ncbi.nlm.nih.gov
60. Linear endoscopic ultrasound: Current uses and future perspectives in mediastinal examination.pubmed.ncbi.nlm.nih.gov
61. Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma.pubmed.ncbi.nlm.nih.gov
62. Advancing Esophageal Cancer Staging and Restaging: The Role of MRI in Precision Diagnosis.pubmed.ncbi.nlm.nih.gov
63. Fully Automated AI-Based Lymph Node Measurements in Chest CT: Accuracy and Reproducibility Compared with Multi-Reader Assessment.pubmed.ncbi.nlm.nih.gov
64. Correlation between tumor mutational burden and CT radiographic features in EGFR exon 19 deletion-mutated lung adenocarcinoma: a diagnostic accuracy study.pubmed.ncbi.nlm.nih.gov
65. Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion From the Children's Oncology Group, European paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.pubmed.ncbi.nlm.nih.gov
66. Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma.pubmed.ncbi.nlm.nih.gov
67. Complete response of a giant metastatic neck mass in tonsillar squamous cell carcinoma achieved with radiotherapy combined with immunotherapy: a case report.pubmed.ncbi.nlm.nih.gov
68. All-site radiotherapy for metastatic ewing's sarcoma: a short-term analysis of feasibility, response, and safety.pubmed.ncbi.nlm.nih.gov
69. Radiologists and treatment response assessment: conventional and functional radiological criteria for predicting therapeutic response in virus-related and non-virus-related cancers.pubmed.ncbi.nlm.nih.gov
70. Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209).pubmed.ncbi.nlm.nih.gov
71. Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.pubmed.ncbi.nlm.nih.gov
72. Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.pubmed.ncbi.nlm.nih.gov
73. A prospective pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors.pubmed.ncbi.nlm.nih.gov
74. Insights on Oligometastatic Non-Small-Cell Lung Cancer.pubmed.ncbi.nlm.nih.gov
75. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.pubmed.ncbi.nlm.nih.gov
76. Tumor-Informed ddPCR for Personalized Longitudinal ctDNA Monitoring in Advanced Solid Tumors: Molecular-Radiological Concordance and Molecular Lead Time.pubmed.ncbi.nlm.nih.gov
77. [^99mTc]Tc-FAPI-04 SPECT/CT for initial staging of gastrointestinal malignancies: a prospective comparison with contrast-enhanced CT.pubmed.ncbi.nlm.nih.gov
78. Double Diagnostic Dilemma in Metaplastic Breast Carcinoma.pubmed.ncbi.nlm.nih.gov
79. Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma.pubmed.ncbi.nlm.nih.gov
80. Characteristic CT Imaging Features of Atraumatic Peritoneal and Subperitoneal Pathologies in Emergency Settings: A Pictorial Review.pubmed.ncbi.nlm.nih.gov
81. Update on Renal Cell Carcinoma Diagnosis with Novel Imaging Approaches.pubmed.ncbi.nlm.nih.gov
82. Tips and Tricks in Thoracic Radiology for Beginners: A Findings-Based Approach.pubmed.ncbi.nlm.nih.gov
83. Lipoid Pneumonia: HRCT and MRI Spectrum, Diagnostic Pitfalls, and Imaging-Based Diagnostic Workflow.pubmed.ncbi.nlm.nih.gov
84. Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.pubmed.ncbi.nlm.nih.gov
85. Spectrum of Imaging Patterns of Lung Cancer following Radiation Therapy.pubmed.ncbi.nlm.nih.gov
86. Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision-Making, a Review.pubmed.ncbi.nlm.nih.gov
87. The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.pubmed.ncbi.nlm.nih.gov
88. Therapeutic Time Migration in Hepatocellular Carcinoma: Rethinking the Timing of Systemic Therapy Across the Disease Continuum.pubmed.ncbi.nlm.nih.gov
89. Modified RECIST submodels and ordinal regression model predict neoadjuvant chemoimmunotherapy response in locally advanced gastric cancer​​.pubmed.ncbi.nlm.nih.gov
90. Setting the standard: empirical benchmarks for case-level site-central discordance in radiographic endpoints in oncology clinical trials.pubmed.ncbi.nlm.nih.gov
91. Comprehensive review of post-treatment imaging in head and neck cancers: from expected to unexpected and beyond.pubmed.ncbi.nlm.nih.gov
92. Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.pubmed.ncbi.nlm.nih.gov
93. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.pubmed.ncbi.nlm.nih.gov
94. Magnetic Resonance-Guided Radiotherapy for Unresectable Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Series and Review of Treatment Options.pubmed.ncbi.nlm.nih.gov
95. TACE-HAIC Plus Targeted Therapy and Immunotherapy for HCC with Tumor Thrombus and Arteriovenous Fistula.pubmed.ncbi.nlm.nih.gov
96. Liver transplantation as a treatment for cancer: comprehensive review.pubmed.ncbi.nlm.nih.gov
97. Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response.pubmed.ncbi.nlm.nih.gov
98. From CNNs to SAM: A Survey of Deep Learning Techniques for Liver Tumor Segmentation in CT Images.pubmed.ncbi.nlm.nih.gov
99. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.pubmed.ncbi.nlm.nih.gov
100. DICOM structured reporting and cancer clinical trials results.pubmed.ncbi.nlm.nih.gov
101. Urothelial carcinoma with trophoblastic differentiation: case report and review of literature.pubmed.ncbi.nlm.nih.gov
102. Correlation of the Diagnostic Accuracy of Dual Energy Computed Tomography and Positron Emission Tomography/Computed Tomography in Mediastinal Lymph Node Staging in Lung Cancer: A Systematic Review.pubmed.ncbi.nlm.nih.gov
103. Artificial intelligence for rapid on-site evaluation of lymph node fine-needle aspiration: improving diagnostic efficiency and accuracy.pubmed.ncbi.nlm.nih.gov
104. Radiologic-Pathologic Correlation in Biliary Cystic Neoplasms: Insights From a Single-Centre Experience.pubmed.ncbi.nlm.nih.gov
105. Multiphase CT-derived markers for the characterization of large solid and cystic renal masses by histology and grade.pubmed.ncbi.nlm.nih.gov
106. RADS ALPHABET: news and tips for young and general radiologists.pubmed.ncbi.nlm.nih.gov
107. Metagenomic next-generation sequencing facilitates precision treatment and prognostic improvement in pulmonary cryptococcosis.pubmed.ncbi.nlm.nih.gov
108. Cavitary Pneumonia Causes in the Arid Landscapes of Southern Arizona.pubmed.ncbi.nlm.nih.gov
109. Role of Multidetector Computed Tomography in Differentiation of Benign and Malignant Cavitary Lung Lesions With a Histopathological Correlation: A Retrospective Cross-Sectional Study.pubmed.ncbi.nlm.nih.gov
110. Accuracy of percutaneous ultrasound-guided needle biopsy of abdominal lymph nodes for the diagnosis of malignant disease.pubmed.ncbi.nlm.nih.gov
111. Fusing Radiomics and Ultrasonic Features: A Superior Nomogram for Diagnosing Cervical Tuberculous Lymphadenitis.pubmed.ncbi.nlm.nih.gov

Eğitim amaçlıdır; hasta başında tanı ve tedavi kararının yerine geçmez. İçerik yapay zekâ destekli bir süreçle güncel literatüre göre cümle cümle kaynaklarla karşılaştırıldı, ancak uzman radyolog incelemesinden geçmedi. Klinik kararlarda güncel kılavuzları, kurum protokollerini ve radyoloji raporunu esas alın.